GlassScriptPhysician profile
Vipul M Patel
NPI 1700994613
$7,494.94
in general payments reported to CMS, 2019-2025
44 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $804 · 2021: $858 · 2022: $1,309 · 2023: $1,140 · 2024: $917 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,418.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,459.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,185.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $496.95 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $435.22 | 2019-2025 | |
| Lilly USA, LLC | $359.17 | 2019-2024 | Mounjaro, Lyumjev, Jardiance |
| Novo Nordisk INC | $338.11 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $315.95 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.59 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $244.96 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $228.87 | 2019-2025 | |
| Pfizer INC. | $210.94 | 2019-2022 | |
| Pulmonx Corporation | $209.25 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Astellas Pharma US INC | $178.22 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $159.37 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $154.82 | 2023-2025 | Gemtesa |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.